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Abstract
Selective replication of oncolytic viruses in tumor cells
provides a promising approach for the treatment of human
cancers. One of the limitations observed with oncolytic viruses
currently used in the treatment of solid tumors is the
inefficient spread of virus throughout the tumor mass
following intratumoral injection. Data are presented showing
that oncolytic adenoviruses expressing the relaxin gene and
containing an Ad5/Ad35 chimeric fiber showed significantly
enhanced transduction and increased virus spread throughout
the tumor when compared with non–relaxin-expressing, Ad5-
based viruses. The increased spread of such viruses through-
out tumors correlated well with improved antitumor efficacy
and overall survival in two highly metastatic tumor models.
Furthermore, nonreplicating viruses expressing relaxin did
not increase metastases, suggesting that high level expression
of relaxin will not enhance metastatic spread of tumors. In
summary, the data show that relaxin may play a role in
rearranging matrix components within tumors, which helps
recombinant oncolytic adenoviruses to spread effectively
throughout the tumor mass and thereby increase the extent
of viral replication within the tumor. Expressing relaxin from
Ad5/Ad35 fiber chimeric adenoviruses may prove a potent and
novel approach to treating patients with cancer. [Cancer Res
2007;67(9):4399–407]
Introduction
Oncolytic adenovirus therapies use a unique method of tumor
destruction by selective viral replication and lysis of tumor cells
and therefore represent a novel approach for treating solid tumors
(1). The antitumor efficacy of these oncolytic adenoviruses is,
however, frequently limited due to variable expression levels of
the coxsackievirus-adenovirus receptor (CAR) on tumor cells (2–5),
a cell surface receptor used by Ad5-based viruses to bind and enter
cells (6). By switching the Ad5 fiber knob with the Ad35 knob that
recognizes the highly abundant CD46 receptor on tumor cells (7),
viral entry was significantly improved and correlated well with
enhanced antitumor activity of Ad5/35 chimeric viruses when
compared with Ad5-based viruses (6–8). Although the fiber
chimeric viruses significantly increase virus entry into tumor cells,
the inability of the virus to efficiently spread throughout a big
tumor mass still remains a major obstacle to the development of
a successful adenovirus-based cancer gene therapy for treating
solid tumors (9). Recent evidence has shown that connective tissue
and extracellular matrix (ECM) components may play a prominent
role in inhibiting viral spread following administration of
adenovirus (1, 9, 10), and data suggest that, when ECM is degraded
by proteolytic enzymes, such as trypsin or collagenase, an
enhancement of viral distribution within the tumor can be
observed (11, 12).
Relaxin, a peptide hormone, is involved in softening the uterine
cervix, vagina, and interpubic ligaments by remodeling or
degrading collagen and altering the connective tissue matrix
composition in preparation for mammalian parturition (13–16). In
addition, relaxin is also known to up-regulate matrix metal-
loproteinases (17–20). Based on the important role of relaxin as a
matrix degradative protein, it is hypothesized that relaxin might
facilitate spread of adenovirus within tumors due to the removal of
the ECM that may act as a naturally occurring structural barrier to
virus spread within tumors.
With the aim of improving cell transduction and viral spread of
oncolytic adenoviral vectors within tumors, two relaxin-expressing,
replication-competent vectors were generated that contained
either the wild-type Ad5 fiber or the Ad5/35 chimeric fiber. These
viruses were evaluated for their antitumor efficacy and their effect
on metastatic spread of primary tumors and compared with the
non–relaxin-expressing vectors (6).
The studies show that relaxin expression enhanced the spread
of virus in tumors, in which virus transduction of the parental,
non–relaxin-expressing virus was low overall. In addition, relaxin
expression also controlled metastatic spread of tumor cells and
significantly improved overall survival in tumor-bearing animals.
The relaxin-dependent increase in spread of virus was due to the
degradation and/or modification of the ECM within the tumor
environment.
In summary, Ad5/Ad35 fiber chimeric oncolytic viruses express-
ing relaxin prolong the survival of tumor-bearing animals by
efficiently entering tumor cells and effectively spreading through-
out tumors when compared with Ad5-based oncolytic vectors not
expressing relaxin and may therefore offer a novel and improved
oncolytic therapy for patients with cancer.
Materials and Methods
Construction of relaxin-expressing oncolytic viruses. To generate
relaxin-expressing oncolytic viruses, a shuttle plasmid, CP1730, was
constructed as described below. The relaxin-1 gene was amplified by PCR
using two primers (5¶-AACAGGAGGAGACGACTGACCATGGAGGAGCCG-
CAGTCAGATC-3¶ and 5¶-GCTTTATTATTTTTTTTTATCAGTCTGAGT-
CAGGCCCTTCTG-3¶) and a plasmid (pDNR-LIB-RLX; ref. 21). pDr21F, a
plasmid containing the right end of the Ad5 genome, was digested with
Xho1 and Sph1, and the 11-kb fragment was gel purified and ligated with
the PCR product to generate CP1730. To insert the granulocyte macrophage
colony-stimulating factor (GM-CSF) gene, CP1730 was digested with Xho1
Note: Supplementary data for this article are available at Cancer Research Online
(http://cancerres.aacrjournals.org/).
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and Spe1, and the purified 9.9-kb fragment was ligated with the 2,667-bp
fragment of CG0070 viral DNA (22) that had been digested with the
same enzymes to generate CP1734. This plasmid was digested with Stu1,
AatII, and PacI, and the purified 6,557-bp fragment was combined with
Srf-1–linearized pFLAr20hGM (23) to generate the full-length plasmid
CP1740. The same fragment was also combined with Srf-1–linearized
pFLAr20hGM-5T35H (6) to generate the fiber chimeric full-length plasmid
CP1741. Full-length plasmids were digested with I-Sce-I and transfected
into AE1-2a cells (24) to generate the OV-RLX-5 and OV-RLX-5T35H
viruses. High-titer virus stocks of relaxin and non–relaxin-expressing
oncolytic viruses were generated [7  1012 to 8  1012 viral particles (vp)/
mL] in AE1-2a cells with a particle to plaque-forming unit (pfu) ratio in
the range of 15 to 20 for all viruses (25).
Construction of E1-deficient, relaxin-expressing vectors. To generate
these viruses, a shuttle plasmid, pAd5L&RSma1-CMV-RLX, was con-
structed as described below. The relaxin-1 gene was amplified by PCR
using two primers (5¶-GTTTAAACATGCCTCGCCTG-3¶ and 5¶-GGATCCT-
CAGCAATATTTAG-3¶). The plasmid, pAd5L&RSma-CMV-GFP (6), was
digested with Pme1 and BamH1, and the purified fragment was ligated
with the PCR product to generate pAd5L&RSma-CMV-RLX. Combining
Sma1-linearized pAd5L&RSma1-CMV-RLX and the viral DNA of Ad5GFP
and Ad5GFP-5T35H (6) generated the full-length plasmids pFLAd5CMV-
RLX and pFLAd5/35CMV-RLX. Ad5RLX and Ad5/35RLX viruses were
generated by digesting the full-length plasmids with I-Sce-I and trans-
fecting into AE1-2a cells (23). Nonreplicating viruses used in this study
were produced (3  1011 to 5  1011 vp/mL) with the vp to pfu ratio in the
range of 15 to 20.
Tumor cell lines. The tumor cell lines used in the study were cultured
in RPMI 1640 supplemented with 10% fetal bovine serum (FBS). Human
prostate carcinoma PC-3 cells were purchased from the American
Type Culture Collection, and these cell lines were modified to express
luciferase to generate PC-3.luc (26). A375-mln1.luc is a cell line established
by in vivo selection of lymph node metastases from A375 s.c tumor-bearing
mice (27).
Western blot analysis of relaxin protein expression. To determine
whether the relaxin-expressing replicating and nonreplicating viruses
express the relaxin gene following gene transfer into PC-3.luc and A375-
mln1.luc cells, Western blot analyses were done. Cells were infected with
OV-5, OV-RLX-5, OV-5T35H, OV-RLX-5T35H, Ad5RLX, and Ad5/35RLX
viruses at 200 vp/cell for 36 h. Out of 1 mL supernatant collected, 8 AL from
Ad5RLX- and Ad5/35RLX-infected cells and 25 AL from OV-infected cells
were loaded and run on a 4% to 12% Bis-Tris gel under reducing conditions
and transferred to Invitrolon polyvinylidene difluoride membranes (Invi-
trogen). Colorimetric detection with rabbit polyclonal antibody raised
against full-length human relaxin (1:500; Santa Cruz Biotechnology, Inc.)
and horseradish peroxidase anti-rabbit IgG conjugate antibody (1:5,000;
Santa Cruz Biotechnology) identified the 18-kDa, relaxin-specific band.
Invasion assays. Invasion was measured by assessment of the PC-3 cell
migration rate through an artificial basement membrane in an invasion
chamber (Chemicon International) as described previously (28–30). PC-3
cells were seeded in six-well tissue culture plates at 5  105 cells per well.
The next day, cells were infected with oncolytic viruses at a given dose. After
3 h of incubation, infection medium was removed and replaced with 3 mL
RPMI 1640 containing 10% FBS growth medium, and cultures were
incubated at 37jC for 24 h. After the infection, cells were harvested and cell
suspensions were prepared (1  106 cells/mL) in serum-free medium. After
rehydrating the interior of the inserts with serum-free medium for 2 h, it
was carefully removed and 500 AL of medium containing 10% FBS were
added to the lower chamber. Cell suspension (300 AL) from the infections
was then added to the interior of the inserts. The inserts were incubated
for various durations, and the noninvaded cells and ECM were removed
with a cotton swab. The level of cell invasion was quantified by staining the
cells on the underlying surface of the invasion membrane with crystal violet
and counting them.
In vivo efficacy studies. Female NCR (nu/nu) mice (4–6 weeks of age;
body weight of 18–20 g) were purchased from Simonsen Laboratories. Mice
were injected s.c. in the right flank with either 5  106 PC-3.luc cells (26) or
2  106 A375-mln1.luc cells (injection volume of 100 AL; ref. 27). When
tumors reached the required mean tumor volume (100–125 mm3) as
determined by the formula volume = W  (L)2 / 2 (W is the width and L is
the length, in cubic millimeters), animals were randomly distributed into
treatment groups and received a total of four intratumoral injections, given
once every other day, of 1  1010 vps or PBS in a 50 AL dose volume.
Animals from each group were selected at various time points following the
initial treatment, bled, and euthanized, and tumors were collected. Tumors
were cut into halves, with one half used to detect virus replication and the
other half used to determine viral spread within xenografts by immuno-
histochemistry (6) and to measure the collagen content by trichrome blue
staining (21, 31).
For histologic examination, 5-Am paraffin sections of the tumor tissue
were stained for hexon protein using the Zymed’s Histomouse kit following
the manufacturer’s instructions. The remaining half of the tumor was used
to isolate virus, and the titer was determined by infecting AE1-2a cells with
the extracted virus. Six lymph nodes, including the axillary and inguinal
nodes and the lungs, were collected at the selected time points,
microinjected with 15 mg/mL luciferin substrate, and imaged after 2 min
using the Xenogen imaging system (Xenogen Corp.) to detect luciferase-
positive metastases (27).
Figure 1. Schematic representation of
non–relaxin-expressing (OV-5 and
OV-5T35H) and relaxin-expressing
oncolytic adenoviruses (OV-RLX-5 and
OV-RLX-5T35H). The relaxin-expressing
viruses have a gene encoding human
relaxin-1 replacing gp 14.7 kDa of E3
region. All four viruses have the gene
encoding human GM-CSF replacing gp
19 kDa of the E3 region and the SV40
poly(pA) signal upstream of the
tumor-specific promoter driving E1a
expression. The expression of E1a in all of
these viruses is placed under the control
of the E2F-1 promoter, and OV-5 and
OV-RLX-5 contain the wild-type Ad5 fiber,
whereas OV-5T35H and OV-RLX-5T35H
contain the Ad5 shaft and Ad35 knob.
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Results
Construction of relaxin-expressing oncolytic adenoviruses.
The parental Ad5 and fiber chimeric Ad5/35 oncolytic adenoviruses
carrying relaxin were constructed to study the effect of relaxin
expression on efficiency of virus transduction as well as spread and
overall virus potency in tumor models. The non–relaxin-expressing
parental oncolytic vectors OV-5 and OV-5T35H (6) were engineered
to express relaxin by insertion of the human relaxin-1 cDNA in
place of the 14.7-kDa gene in the E3 region, generating OV-RLX-5
and OV-RLX-5T35H, respectively (Fig. 1). In all the viruses, the
tumor-specific E2F-1 promoter replaced the native E1a promoter
to restrict viral replication to cells that have defects in the pRb
pathway (32–34). In addition, the cDNA encoding human GM-CSF
(hGM-CSF) replaced the open reading frame encoding the 19-kDa
glycoprotein of the E3 region (6). The presence of the hGM-CSF
gene in these viruses does not alter the relative potency of these
vectors in the studies reported here because human GM-CSF is not
active in mice and, in addition, all of the studies are done in
immunodeficient mice.
Expression of relaxin from OV-RLX-5 and OV-RLX-5T35H virus-
infected A375-mln1.luc and PC-3.luc cells was confirmed by an
18-kDa, relaxin-specific band in the Western blots (Fig. 2). Higher
intensity bands with the relaxin-expressing chimeric virus OV-RLX-
5T35H, compared with the relaxin-expressing Ad5-based virus
OV-RLX-5, in both cell lines confirm the higher transduction
efficiency of tumor cell lines by the fiber-modified viruses.
Relaxin-expressing oncolytic adenoviruses enhance the in vitro
invasiveness of PC-3 cells. To test the potential for increasing
metastatic events by the expression of relaxin in cells, an in vitro
cell invasion model system was used (18, 35, 36).
In this model, cell invasion is evaluated by determining the
number of cells that migrate from one chamber to another through
an ECM-based membrane. The effect of relaxin expression on the
level of cell invasion was determined using PC-3 cells infected with
OV-5 or OV-RLX-5 at 50 vp/cell for 24 h and loaded into the
chamber above the ECM membrane. After 16 h, the number of cells
that had migrated through the membrane was determined.
Although the frequency of cell invasion in PC-3 cells infected with
OV-5 was identical to uninfected PC-3 cells, at least twice as many
cells infected with OV-RLX-5 migrated to the lower chamber
(Fig. 3A), suggesting that the expression of relaxin can increase
the invasiveness of these tumor cells in this in vitro model system.
Due to the high infectivity of the chimeric viruses, PC-3 cells were
infected with these viruses with a multiplicity of infection (MOI) of
1. Under these conditions, the level of invasion of OV-RLX-5T35H–
infected cells was again twice that of the OV-5T35H–infected cells
(Fig. 3B), confirming that relaxin expression in PC-3 cells can
increase the invasiveness of these cells in vitro . In summary, the
increased invasiveness of relaxin-expressing PC-3 cells in vitro
supports the hypothesis that relaxin may degrade ECM compo-
nents, which may lead to a potential increase in metastatic events
in vivo .
Efficacy of relaxin-expressing viruses in A375-mln1.luc
tumor-bearing mice. To determine whether the ability of relaxin
to degrade the ECM enhances virus spread and therefore improves
antitumor efficacy in tumor-bearing mice, relaxin-expressing and
non–relaxin-expressing viruses were tested in two highly meta-
static xenograft models. To test the effect of relaxin in the context
of Ad5- and Ad5/35-based oncolytic viruses in vivo , the non–
relaxin-expressing parental and chimeric viruses, and their
corresponding relaxin-expressing viruses, were first tested in a
s.c. metastatic A375-mln1.luc xenograft model. The different
groups were injected either with PBS or 1  1010 vps of OV-5,
OV-5T35H, OV-RLX-5, or OV-RLX-5T35H at each injection for a
total of four injections, and tumor progression was monitored over
time. In the PBS and OV-5 groups, the tumor volume increased 5.3-
and 2.4-fold, respectively, over a period of 18 days (Fig. 4A),
whereas in the OV-RLX-5–treated mice the tumors hardly
progressed during that time, suggesting that the Ad5-based
oncolytic virus carrying relaxin was more potent than the Ad5-
based nonrelaxin virus. In animals treated with either OV-5T35H or
OV-RLX-5T35H, there was minimal tumor progression observed in
either group, most likely due to the high transduction efficiency
and potency of the non–relaxin-expressing chimeric virus in the
A375-mln1.luc model (OV-5T35H, OV-RLX-5, or OV-RLX-5T35H
versus OV-5; P < 0.05). The difference in transduction efficiency
observed between the Ad5-based and the chimeric viruses is due to
the different expression patterns of their respective receptors, CAR
and CD46, in this model. CD46 expression in the A375-mln1.luc
cells is f35-fold higher than CAR (Supplementary Fig. S1A),
resulting in an increased level of virus transduction and overall
potency (Supplementary Fig. S1C) of the chimeric vectors when
compared with Ad5-based viruses. Therefore, in the A375-mln.luc
model, the expression of relaxin from Ad5-based oncolytic vectors
improved the efficacy of the vector, whereas the expression of
relaxin did not further enhance the potency of the Ad5/Ad35
chimeric virus due to the high transduction efficiency and overall
potency observed with the parental chimeric vector. In summary,
the expression of relaxin in the context of an Ad5-based oncolytic
virus enhances antitumor efficacy in the A375-mln.luc tumor
Figure 2. Relaxin (RLX ) expression from oncolytic adenoviral vectors. PC-3.luc cells (lanes 1–4 ) or A375-mln1.luc cells (lanes 5–8 ) were infected with the
relaxin-expressing and non–relaxin-expressing oncolytic vectors at a MOI of 200 vp/cell. At 36 h after infection, supernatants were harvested and 25 AL were loaded
onto an 8% to 12% Bis-Tris polyacrylamide gel and transferred onto a nitrocellulose membrane. Relaxin expression was determined by probing the membrane with
a polyclonal, relaxin-specific antibody. An 18-kDa, relaxin-specific band was found for OV-RLX-5 in PC-3.luc (lane 2 ) and A375-mln1.luc (lane 6) cells and for
OV5-RLX-5T35H in PC-3.luc and A375-mln1.luc cells (lanes 4 and 8 , respectively). No expression was observed from the non–relaxin-expressing vectors OV-5 or
OV-5T35H in PC-3.luc cells (lanes 1 and 3 , respectively) or A375-mln1.luc cells (lanes 5 and 7 , respectively).
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model, whereas no enhancement of potency was observed in this
model when relaxin was expressed from Ad5/Ad35 fiber chimeric,
oncolytic viruses.
Enhanced antitumor efficacy of viruses correlates with
improved viral spread and replication within tumors. To verify
that the increase in therapeutic efficacy with the relaxin-expressing
Ad5-based viruses and the chimeric viruses was due to an increase
in viral spread and replication, the number of hexon-positive cells
and infectious vps within the tumors following virus administration
was determined. Tumors were harvested on day 17 following virus
injections, and the number of hexon-positive cells was determined
by immunohistochemical staining. An increase in hexon-positive
cells was found in tumors treated with OV-5T35H and OV-RLX-
5T35H (Fig. 4B) compared with tumors treated with OV-RLX-5 and
OV-5. The number of hexon-positive cells was slightly lower in the
tumors treated with OV-RLX-5 compared with tumors treated with
either chimeric vector. There was a further decrease in the number
of hexon-positive cells in the tumors treated with OV-5 when
compared with the tumors treated with the other OVs. No hexon-
positive cells were seen in the control tumors injected with PBS. To
further confirm virus replication, a portion of the tumor was used
to quantify the infectious vps by titering tumor homogenates on
AE1-2a cells (24). There was no significant difference in the level of
infectious virus found in tumors from animals treated with either
chimeric virus, and there was a slight decrease (f3- to 5-fold) in
the tumors treated with OV-RLX-5 compared with the chimeric
viruses. In contrast, there was a 50-fold drop in the amount of
infectious virus in the tumors treated with OV-5 compared with
the tumors treated with OV-RLX-5 at day 17 (Fig. 4C). Approx-
imately 2-log more virus was detected in the tumors treated with
either chimeric virus when compared with tumors treated with
OV-5 (Fig. 4C).
These data suggest that the level of virus spread and infectious
particles found in the A375-mln1.luc tumors following treatment
with these viruses correlate well with the antitumor efficacy in vivo
as high levels of virus spread and infectious particles present in
tumors result in minimal tumor progression. The data also suggest
that, in the context of Ad5-based vectors, the expression of relaxin
significantly increases the level of viral spread and overall potency
of the vector in this particular model. However, for the chimeric
virus platform, the expression of relaxin did not enhance the
already potent antitumor activity of the virus due to the high
infectivity of the chimeric viruses in the A375-mln1.luc tumor
model.
Relaxin expression from adenoviral vectors does not
enhance the metastatic events in mice bearing highly
metastatic A375-mln1.luc tumors. To evaluate whether the
increased invasiveness of relaxin-expressing cells in vitro would
translate into potentially enhanced metastatic spread of tumors
in vivo , the formation of metastases in animals treated with the
oncolytic viruses in the study described above was monitored.
Mice were sacrificed on study day 12, and the presence of tumor
cells in lymph nodes and lungs was determined by evaluating the
level of luciferase activity in the pooled organs after direct injection
with luciferin. The average total photon counts observed in lymph
nodes and lungs in the oncolytic virus-treated groups were greatly
reduced when compared with organs from PBS-treated animals
(Fig. 4D), indicating that the metastatic spread of tumor cells was
controlled in virus-treated animals. There was an f3-fold
reduction in the photon counts in the OV-5–treated group
compared with the PBS group. In OV-RLX-5–treated and OV-
5T35H–treated animals, an f6-fold and f2-fold decrease in
photon counts was observed compared with either the PBS-treated
or OV-5–treated groups, respectively. The OV-RLX-5T35H–treated
mice exhibited the lowest photon counts in lymph nodes and lungs
at this time point, f2.5-fold lower than those from OV-RLX-5–
treated and OV-5T35H–treated mice. Thus, the relaxin-expressing,
vector-treated groups had a reduction in the level of metastasis
compared with their parental, non–relaxing-expressing, virus-
treated groups. In summary, the in vitro data showing an increase
in the invasiveness of tumor cells do not correlate with the
decrease in the level of metastasis seen in vivo .
To further investigate whether high level expression of relaxin
within tumors without the oncolytic activity would increase the
metastatic events in tumor-bearing mice and therefore pose a
potential safety risk in the use of such viruses, parental and relaxin-
expressing nonreplicating viruses Ad5GFP, Ad5/35GFP, Ad5RLX,
and Ad5/35RLX were tested in the A375-mln1.luc model using the
same virus doses and treatment schedules as described above. The
Western blot analysis of supernatants from virus-infected cells
confirmed the presence of the 18-kDa, relaxin-specific band in both
cell lines (Fig. 5B). Higher intensity bands with Ad5/35RLX,
compared with the Ad5RLX, in both cell lines again confirmed
the higher transduction efficiency of these tumor cell lines by the
fiber-modified viruses. Furthermore, higher intensity of relaxin-
specific bands was also observed with all of the relaxin-expressing
nonreplicating viruses compared with the replicating viruses due to
Figure 3. Relaxin expression increases the invasiveness of PC-3 cells in an
in vitro cell invasion assay. PC-3 cells were infected either with parental (OV-5)
or relaxin-expressing Ad5-based oncolytic vectors (OV-RLX-5) at a MOI of
50 vp/cell for 24 h (A ) or with parental (OV-5T35H) or relaxin-expressing
(OV-RLX-5T35H) chimeric oncolytic vectors at a MOI of 1 vp/cell for 24 h (B ).
Uninfected PC-3 cells were used as control. Infected or control cells were placed
in the upper invasion chamber for 16 h (A) or 8 h (B ) for migration through
the ECM to occur. Cells that migrated through the ECM were stained with crystal
violet, and three high-power fields were counted (40) and plotted as mean
cells/field. Columns, mean (n = 2); bars, SD.
Cancer Research
Cancer Res 2007; 67: (9). May 1, 2007 4402 www.aacrjournals.org
Research. 
on June 2, 2014. © 2007 American Association for Cancercancerres.aacrjournals.org Downloaded from 
the use of the strong constitutive cytomegalovirus (CMV) promoter
driving relaxin expression in these viruses (Figs. 2 and 5B).
No antitumor efficacy was observed with any of the non-
replicating viruses (Fig. 5C) in the A375-mln1.luc model, indicating
that the relaxin protein itself has no antitumor effect that translates
into a reduced tumor growth rate. Selected mice (n = 3) were
sacrificed on study day 12 to monitor metastasis in lymph nodes
and lungs. All the mice in the groups treated with the non-
replicating viruses were positive for luciferase activity, and the
average total photon counts of all those groups were similar to the
photon counts of PBS-injected control animals (Fig. 5D), suggest-
ing that the high level expression of relaxin intratumorally in the
absence of any oncolytic activity does not increase the metastatic
potential of the tumor in the highly metastatic A375-mln1.luc
model. In summary, although the expression of relaxin increased
the level of tumor cell invasion in an in vitro assay, relaxin-
expressing oncolytic adenoviruses and non–relaxin-expressing,
fiber chimeric oncolytic viruses decreased the number of
metastases at distant sites in a highly metastatic tumor model
in vivo , suggesting that the increased potency of these viruses in
controlling tumor growth, as observed earlier, probably leads to a
reduction in metastasis at distant sites. The results also show that
the viruses expressing relaxin without the capability to replicate or
kill tumor cells do not increase the metastatic events, although
those nonreplicating viruses expressed very high levels of relaxin
in vitro and did not control growth of the primary tumors (Figs. 2
and 5B).
Relaxin expression enhances the antitumor efficacy of fiber
chimeric viruses in PC-3.luc tumor-bearing mice. The relaxin-
expressing and non–relaxin-expressing chimeric oncolytic viruses
were tested further in the highly metastatic PC-3.luc xenograft
model. This model was specifically chosen for evaluating the
potency of the chimeric oncolytic viruses because of the reduced
transduction efficiency of PC-3.luc cells by these vectors compared
with A375-mln1.luc cells. The reduced transduction efficiency
offered the potential of detecting a benefit by expressing relaxin in
the context of chimeric oncolytic viruses as had been observed
with the Ad5-based viruses in the A375-mln1.luc model. Although
CD46 receptors are highly expressed in both A375-mln1.luc and
PC-3.luc cells (Supplementary Fig. S1A and B), the transduction of
chimeric virus was only 50% in PC-3.luc cells compared with >90%
in A375-mln1.luc cells at a MOI of 50 (Supplementary Fig. S1A and
B). This is most likely due to very low level expression of the
integrins aVh3 and aVh5 found in PC-3.luc cells, which serve as
coreceptors for internalization of virus bound to the cell surface
receptor (Supplementary Fig. S1A and B). The high level expression
of CARs found in PC-3.luc cells compared with the A375-mln1.luc
cells resulted in the Ad5-based vector being almost as potent in this
model as the chimeric virus (Supplementary Fig. S1D). Thus, only
the chimeric viruses were tested in the PC-3.luc model. Tumors
Figure 4. Enhanced antitumor efficacy of relaxin-expressing vectors in an A375 metastatic melanoma model. Nude mice bearing s.c. A375-mln1.luc tumors were
injected intratumorally when the average tumor size reached f100 mm3 with either PBS, relaxin-expressing (OV-RLX-5 and OV-RLX-5T35H), or parental oncolytic
viruses (OV-5 and OV-5T35H) with 1  1010 vp/mouse/injection once every other day for a total of four injections, and the tumor volume (A) was determined by
caliper measurement. Points, mean tumor volume (mm3; n = 10 per group); bars, SE. A statistically significant delay in tumor progression was observed between all
vector-treated groups compared with PBS-injected mice (OV-5, P < 0.01; OV-5T35H, OV-5T35H, and OV-RLX-5T35H, P < 0.0001) and between relaxin-expressing
vectors (OV5-RLX and OV-RLX-5T35H) compared with the Ad5 parental vector (OV-5, P < 0.05). Seventeen days following the initial viral injection, tumors were
harvested (n = 3) and analyzed for virus spread by determining the number of hexon-positive cells by immunohistochemistry on paraffin-embedded tumor tissue (B) and
for the amount of infectious virus by titering tumor lysates on AE1-2A cells (C ). The level of metastasis after virus treatment was evaluated in animals (n = 3) on
day 12 after virus injections (D) by isolating lungs and selected lymph nodes and injecting them with luciferin to determine photon counts using the Xenogen system.
Level of metastasis as indicated by the combined average total photon counts from lungs and lymph nodes.
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were injected with PBS, OV-5T35H, or OV-RLX-5T35H with the
same doses and treatment schedules as described above, and the
growth of the primary tumor as well as the formation of metastases
in lymph nodes and lungs were monitored.
Within 26 days after the first viral injections, tumors of PBS-
treated animals increased 8-fold in size (Fig. 6A) in contrast to
tumors from OV-RLX-5T35H–treated animals, which had only
increased 1.6-fold. A slight but significant (P < 0.0001) increase in
tumor burden (4.2-fold) was noted in mice treated with OV-5T35H
when compared with the OV-RLX-5T35H–treated group. These
data suggest that relaxin expression from fiber chimeric oncolytic
viruses can lead to enhanced potency when compared with non–
relaxin-expressing, fiber chimeric viruses in models in which the
initial transduction of these viruses is limited.
Disruption of the collagen network within tumors enhances
virus spread. To evaluate whether the increase in therapeutic
efficacy of OV-RLX-5T35H in the PC-3.luc model was due to an
increase in virus spread, tumors were harvested on day 28
following initial virus injection, and the number of hexon-positive
cells as well as the amount of infectious vps present in the tumor
were determined as described above. In the PC-3.luc tumors
treated with OV-RLX-5T35H, there was an increase in the number
of hexon-positive cells compared with OV-5T35H–injected tumors
(Fig. 6B, top). When the tumors were stained with Mason’s
trichrome blue, which stains collagen (21, 31, 37), reduced staining
was observed in tumors treated with the relaxin-expressing
chimeric virus compared with the parental chimeric virus or the
PBS-injected tumors (Fig. 6B, bottom), suggesting that there might
be a relaxin-mediated alteration in the collagen bundles or a
reduction in the total collagen amount. When the tumor
homogenates were titered on AE1-2a cells (24), there was an
f5-fold increase in the level of infectious virus present in PC-
3.luc tumors treated with OV-RLX-5T35H compared with tumors
from animals treated with OV-5T35H (data not shown). These
data suggest that chimeric oncolytic vectors expressing relaxin
show better antitumor potency than non–relaxin-expressing
chimeric oncolytic vectors by modifying or degrading the tumor
matrix and therefore enhancing overall virus spread within
tumors.
Relaxin-expressing chimeric oncolytic viruses control me-
tastases in PC-3.luc tumor-bearing mice leading to prolonged
overall survival. The performance of these chimeric oncolytic
viruses was further evaluated in this model by measuring
metastases in lymph nodes and lungs. PC-3.luc tumors were
injected with the same virus doses and treatment schedules as
described above. Forty-two days after the initial viral injection
(study day 42), the percentage of mice with metastases in either
lymph nodes or lungs in PBS-treated, OV-5T35H–treated, and
Figure 5. Relaxin-expressing, replication-deficient adenovirus vectors do not enhance metastatic spread of A375-mln1.luc tumors. A, a green fluorescent protein
(GFP ) reporter gene under the control of a strong constitutive CMV promoter was incorporated into the E1 region of adenoviral vectors that contained the fiber knob
from either Ad5 (Ad5GFP) or Ad35 (Ad5/35GFP) adenovirus. The GFP reporter gene was replaced with the human relaxin-1 gene to generate the relaxin-expressing
nonreplicating viruses with the Ad5 fiber (Ad5RLX) or the Ad5/35 fiber (Ad5/35RLX). B, the level of relaxin expression from these nonreplicating adenoviral vectors
was determined by Western blot analysis. PC-3.luc cells or A375-mln1.luc cells were infected with the relaxin-expressing nonreplicating viruses at a MOI of 200 vp/cell
for 36 h, and 8 AL of the supernatants were loaded onto an 8% to 12% Bis-Tris polyacrylamide gel that was transferred to a nitrocellulose membrane. Relaxin
protein was detected as described in the legend of Fig. 2. The relaxin-specific, 18-kDa band was observed for Ad5RLX in PC-3.luc (lane 9) and A375-mln1.luc (lane 11)
cells and for Ad5/35RLX in PC-3.luc and A375-mln1.luc cells (lanes 10 and 12 , respectively). To evaluate the antitumor efficacy of these viruses in the A375-mln1.luc
model, nude mice bearing s.c. A375-mln1.luc tumors (n = 10) were injected intratumorally with PBS or relaxin or the non–relaxin-expressing nonreplicating viruses
(Ad5RLX, Ad5/35RLX, Ad5GFP, and Ad5/35GFP) with 1  1010 vp/mouse/injection once every other day for a total of four injections. Tumor volume (C ) was
determined by caliper measurement. Points, mean tumor volume (mm3; n = 10 per group); bars, SE. The level of metastasis was evaluated on day 12 after virus
injections (D ) by isolating lungs and selected lymph nodes and injecting them with luciferin to determine photon counts using the Xenogen system. Combined total
average photon counts from the lungs and lymph nodes (n = 3).
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OV-RLX-5T35H–treated groups was 80, 27, and 0, respectively
(Fig. 6C). In summary, relaxin-expressing, chimeric oncolytic
adenovirus treatment decreased the number of metastases in
lymph nodes and lungs in two highly metastatic tumor models,
suggesting that the increased potency of these viruses in
controlling growth of the injected primary tumor most likely leads
to a reduction in metastasis at distant sites.
To evaluate whether the improved efficacy of these vectors in
controlling tumor progression and metastases translates into
improved survival, the study was repeated with survival as the
end point. PBS-injected animals had a mean survival time (MST) of
42 days with no animals alive by day 62 (Fig. 6D), whereas a
significant improvement in survival was observed in the OV-
5T35H–treated mice with a MST of 78 days and 42% of animals
alive at the end of the study on day 95. A further improvement in
survival was observed in the OV-RLX-5T35H–treated group, with
the MST not yet reached by day 95 and 83% of the animals alive at
that time point. Interestingly, complete tumor regression was noted
in 3 of 12 mice treated with either the OV-5T35H or the OV-RLX-
5T35H viruses. These survival data confirm that chimeric oncolytic
vectors expressing relaxin show greater antitumor efficacy and
therefore lead to improved survival of treated animals when
compared with non–relaxin-expressing, fiber chimeric oncolytic
vectors.
Discussion
The inability of Ad5-based oncolytic viruses to consistently
transduce a broad range of tumor cells and efficiently spread
throughout solid tumors seems to hamper their effectiveness in
clinic (1, 33). A fiber knob replacement strategy, generating viruses
with chimeric fibers, has previously been shown to improve the
transduction efficiency of such viruses significantly (6). In the study
described here, the fiber chimeric viruses were combined with a
strategy aiming at increasing spread of viruses within tumors by
introducing the gene for a matrix-degrading peptide hormone into
these viruses. Because the ECM is known for its role in limiting
virus spread throughout tumors (15, 38, 39), the relaxin gene was
incorporated into the OV backbone to degrade/decrease matrix
components following virus infection of tumor cells, thereby
potentially improving virus spread throughout the tumor (16, 21).
Kim et al.’s recent finding also supports the idea of improving
spread with a relaxin-expressing oncolytic virus (21).
Our data suggest that relaxin expression in the context of Ad5-
based and fiber chimeric oncolytic viruses enhances the potency of
such viruses if it is limited due to poor initial transduction
efficiency. Both relaxin-expressing oncolytic viruses and the non–
relaxin-expressing, fiber chimeric oncolytic viruses were more
efficacious in controlling tumor growth than the non–relaxin-
expressing, Ad5-based virus (P < 0.05) in A375-mln1.luc model.
Figure 6. Relaxin expression increases the antitumor efficacy of fiber chimeric viruses in a spontaneous metastatic prostate cancer (PC-3.luc) model. Nude mice
bearing s.c. PC-3.luc tumors (n = 33) were injected intratumorally with PBS, the parental virus (OV-5T35H), or relaxin-expressing virus (OV-RLX-5T35H) with 1  1010
vp/mouse/injection once every other day for a total of four injections. The tumor volume (A) was determined by caliper measurement. Points, mean tumor volume
(mm3; n = 33 per group); bars, SE. A significant difference in tumor progression was observed between the PBS-treated and vector-treated groups (P < 0.0001) and
between the parental chimeric (OV-5T35H) and relaxin-expressing chimeric viruses (OV-RLX-5T35H; P < 0.0001). B, top, twenty-eight days following the initial
viral injections, tumors were harvested and immunohistochemistry was done on tumor sections to determine virus spread by measuring the number of hexon-positive
cells; bottom, at the same time point, the level of collagen within the tumor was evaluated by trichome blue staining. The level of metastasis after virus treatment
was evaluated in the animals on day 42 after virus injections (C ) as described in the legend of Fig. 5. D, to evaluate the effect of these viruses on overall survival in the
PC-3.luc model, animals were treated (n = 12) as described above and monitored for survival for up to 95 d.
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Although there was no difference seen in the efficacy between OV-
RLX-5T35H and OV-5T35H due to the potent efficacy of the non–
relaxin-expressing chimeric vectors in this particular model, the
addition of relaxin to the Ad5-based virus resulted in a dramatic
increase in potency to a level comparable with the chimeric viruses.
This increase in potency was due to an increase in virus spread
within tumors as indicated by the increase in hexon-positive cells.
The increased virus spread correlated with an increase in the level
of infectious virus within the tumor, which in turn led to an
improved ability to control tumor growth. In the A375-mln1.luc
model, the difference in activity of the fiber chimeric vectors versus
Ad5-based viruses is most likely due to the difference in the level of
their respective receptors, with the CAR used by Ad5-based viruses
low with respect to the CD46 receptor that is used by the Ad5/35
fiber chimeric viruses (7). The difference in the expression of the
two receptors correlates with the poor transduction efficiency and
overall antitumor potency of Ad5-based viruses and the good
transduction efficiency and potency of fiber chimeric viruses in this
model.
To determine if the expression of relaxin could increase the
potency of fiber chimeric oncolytic vectors in some models, a
second metastatic model was tested in which the fiber chimeric,
parental vectors showed lower transduction efficiency. In support
of the hypothesis described above, the relaxin-expressing, fiber
chimeric virus showed significantly better antitumor efficacy in
the metastatic PC-3.luc model when compared with the non–
relaxin-expressing, fiber chimeric virus (P < 0.0001). In this study,
metastatic events were greatly reduced with the virus treatment,
and unlike in the in vitro studies, the metastatic events were
further reduced with the relaxin-expressing virus compared with
the non–relaxin-expressing, fiber chimeric virus. Interestingly, the
increased potency of the relaxin-expressing, fiber chimeric virus in
this model correlated with an enhanced degradation and/or
structural modification of collagen within the matrix in the
relaxin-expressing, virus-treated groups and overall spread of the
virus within the tumor mass (40). This modification of the ECM
potentially removes some of the structural barriers within the tumor
that prevents effective virus spread (16). Kim et al. also showed a
reduction in the level of collagen staining within tumors after
treatment with relaxin-expressing viruses and proposed that this
reaction was due to a degradation of the ECM, which slowed down
tumor growth (21).
In the study presented, the increased virus spread, as indicated
by the increase in number of hexon-positive cells, allowed a
greater level of virus replication within tumors, which ultimately
lead to an increase in antitumor potency. As was observed in the
A375-mln1.luc model, the growth rate of the primary tumor and
the number of metastases were controlled or reduced in the
metastatic PC-3.luc model in the relaxin-expressing, virus-treated
animals when compared with animals treated with the non–
relaxin-expressing virus, which contradicts with the data we saw
in our in vitro studies that relaxin expression could increase cell
invasion.
This apparent discrepancy could be due to the fact that the
in vitro assay evaluates only a few steps necessary for metastases
to occur (e.g., mobility and invasion of cells), whereas in the
in vivo models all steps, including dissociation of cells from the
primary tumor, enhanced cell motility, and the ability of cells to
invade stroma and to grow effectively at distant sites, are required
for metastasis to occur (29, 41). If relaxin is able to only affect one
or a few of these steps of the complex metastatic process, it might
not lead to increased metastatic events in tumor models.
Alternatively, due to the enhanced antitumor potency of the
relaxin-expressing viruses, these viruses effectively control the
growth of the primary tumor and therefore indirectly may control
the spread of the tumor cells to distant sites because this process
is related to the size of the primary tumor in these models (27).
However, the relaxin-expressing, replication-incompetent viruses
do not increase the metastasis in a highly metastatic tumor model,
suggesting that even strong overexpression of relaxin within
growing tumors will not increase their metastatic potential.
In conclusion, the data presented herein suggest that, by
replacing the fiber knob of Ad5-based viruses with the Ad35 fiber
knob and/or introducing the relaxin gene into the oncolytic
adenoviral backbone, transduction efficiency of viruses and the
spread of the virus within solid tumors can be significantly
improved, leading to prolonged survival of tumor-bearing mice.
Thus, oncolytic viruses with Ad5/35 fibers, expressing the relaxin
gene, may offer a novel promising therapy for the treatment of
patients with cancer.
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Correction: Adenovirus Prolongs Survival of
Tumor-Bearing Mice
In the article on how adenovirus prolongs survival of tumor-
bearing mice in the May 1, 2007 issue of Cancer Research (1), the
Acknowledgments should have read as follows:
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